Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.30 (3.59%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £56.68m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Contract Win

4 Aug 2014 07:00

RNS Number : 1000O
Kromek Group PLC
04 August 2014
 



Embargoed until: 07.00, 4 August 2014

 

 

Kromek Group plc

("Kromek" or "the Company")

 

 

Kromek Awarded Network Detector Development Programme by the US Defence Advanced Research Projects Agency

 

 

Kromek (AIM: KMK.L), a supplier of patented radiation detection technologies to the medical, security and nuclear markets, is pleased to announce that it has been awarded up to $1.23m for a 12-month programme with the U.S. Defense Advanced Research Projects Agency (DARPA) commencing immediately. This is to develop an advanced portable detection system for gamma and neutron radiation that can be combined in large networks, providing information on radiation signatures over an extended area. The programme is geared towards procurement in Year 2 and beyond. DARPA is an agency of the United States Department of Defense and responsible for maintaining the technological superiority of the U.S. military.

 

This contract, along with many others in the nuclear detection market, represents further healthy conversion of the pipeline into orders and the majority of the revenue of the contract is expected to be recognised in the current financial year.

These latest successes are rooted both in Kromek's world leading capabilities in high performance radiation detectors, which are compact and uniquely require no cooling mechanism, and also in its overall "semiconductor to solutions" business model. This allows the Company to quickly respond to emerging customer needs by understanding and integrating all the closely interlocking elements required for an end customer application. These elements often include the detector design, different system configurations and software components, to allow improved interpretation and presentation of data in an easy-to-use and efficient form. Over the last few years the Company has introduced a number of products into the nuclear detection market, each providing unique performance, field usability and reduced size, including the world's smallest, high resolution gamma ray spectrometer operating at room temperature. This is used for a wide range of applications such as nuclear decommissioning, environmental monitoring and remote sensing on board ground-based robotics and Unmanned Aerial Vehicles.  

Commenting on the award, Kromek CEO Dr Arnab Basu said, "Kromek is delighted to receive this award from DARPA, which closely follows recent awards from other areas of the U.S. Government and is further recognition of the advances Kromek's detector technology platforms are making into growing global markets."

 

-ends-

 

 

For further information, please contact:

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley

Broking

Charles Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

John West

Andrew Dunn

Tel: 020 7920 3150

 

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUMCRUPCGQG
Date   Source Headline
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:55 pmRNSHolding(s) in Company
28th Feb 201912:50 pmRNSHolding(s) in Company
26th Feb 201912:56 pmRNSDirector Dealings
26th Feb 20197:00 amRNSNuclear security contract with new OEM customer
25th Feb 20191:02 pmRNSResults of General Meeting and Open Offer and TVR
7th Feb 20197:00 amRNSFirm Placing and Open Offer and Notice of GM
28th Jan 20197:00 amRNSKromek Awarded $58m Medical Imaging Contract
14th Jan 20197:00 amRNSInterim Results
18th Dec 20187:00 amRNSNotice of Results
10th Dec 20187:00 amRNSKromek awarded first biological contract by DARPA
19th Nov 20187:00 amRNSFive-year $7.8m baggage screening contract
1st Oct 20185:12 pmRNSResult of AGM and Directorate Change
27th Sep 20187:00 amRNSKromek awarded $1.8m funding from DTRA
7th Sep 20182:57 pmRNSNotice of AGM and Posting of Annual Report
20th Aug 20187:00 amRNSKromek wins two new contracts in medical division
23rd Jul 20187:00 amRNSKromek secures two contracts from US government
17th Jul 20187:00 amRNSKromek radiation detectors used during NATO Summit
2nd Jul 20187:00 amRNSFinal Results
30th May 20187:00 amRNSFive-year contract from existing medical customer
1st May 20187:00 amRNSTrading Update
23rd Apr 20187:00 amRNSAward of Molecular Breast Imaging Device project
12th Mar 20187:00 amRNSAward of $1.6m extension to contract by DARPA
11th Jan 20187:00 amRNSAppointment of Joint Broker
19th Dec 20177:00 amRNSInterim Results
27th Nov 20177:00 amRNSNotice of Results
31st Oct 20174:13 pmRNSTotal Voting Rights
13th Oct 20177:00 amRNSDirector/PDMR Shareholding
10th Oct 20179:50 amRNSDirector/PDMR Shareholding
26th Sep 201712:12 pmRNSResult of AGM
26th Sep 20177:00 amRNSDirectorate Change
19th Sep 20174:43 pmRNSExercise of Options
4th Sep 20177:00 amRNSNew five-year security screening contract
1st Sep 201710:49 amRNSNotice of AGM and Posting of Annual Report
31st Aug 201710:51 amRNSTotal Voting Rights
17th Aug 20177:00 amRNSAward of Five-Year Contract from BMD Customer
10th Jul 201712:00 pmRNSPublication of Annual Report
28th Jun 20177:00 amRNSFinal Results
12th Jun 20177:00 amRNSKromek Radiation Detectors Used During Trump Visit
1st Jun 20171:34 pmRNSTotal Voting Rights
2nd May 201712:23 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSTrading Update
5th Apr 201712:18 pmRNSBlock listing Interim Review
29th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20177:00 amRNSAward of New Contract for Radiation Detectors
22nd Feb 20177:00 amRNSFive-Year Contract in Security Screening Market
15th Feb 20174:35 pmRNSHolding(s) in Company
15th Feb 201712:54 pmRNSHolding(s) in Company
15th Feb 201712:51 pmRNSHolding(s) in Company
14th Feb 20175:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.